A phase i study of daily treatment with a ceramide-dominant triple lipid mixture commencing in neonates

BMC Dermatology

Volumn 12, Issue , 2012, Pages

  Lowe, Adrian J ^a,b   Tang, Mimi L K ^a,b   Dharmage, Shyamali C ^a,b   Varigos, George ^a   Forster, Della ^c,d   Gurrin, Lyle C ^a,b   Robertson, Colin F ^a,b   Abramson, Michael J ^e   Allen, Katrina J ^a   Su, John ^a,b,e  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL WOMEN'S HOSPITAL   (Australia)

^d LA TROBE UNIVERSITY   (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

Asthma; Atopy; Eczema; Eczema prevention; Skin barrier function

Indexed keywords

CERAMIDE; DERMATOLOGICAL AGENT; EPICERAM; LIPID; UNCLASSIFIED DRUG; CHOLESTEROL; FATTY ACID;

ALLERGIC DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ECZEMA; FACIAL ECZEMA; FAMILY HISTORY; FEMALE; HUMAN; HYDRATION; INFANT; MALE; MOTHER; NEWBORN PERIOD; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PH MEASUREMENT; PHASE 1 CLINICAL TRIAL; PREVENTIVE MEDICINE; SKIN FUNCTION; SKIN MANIFESTATION; SKIN WATER LOSS; TREATMENT DURATION; WATER LOSS; AUSTRALIA; CLINICAL TRIAL; DRUG COMBINATION; EMULSION; FOLLOW UP; NEWBORN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AUSTRALIA; CERAMIDES; CHOLESTEROL; DRUG COMBINATIONS; ECZEMA; EMULSIONS; FATTY ACIDS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT, NEWBORN; MALE; MEDICATION ADHERENCE;

EID: 84859167186     PISSN: None     EISSN: 14715945     Source Type: Journal    
DOI: 10.1186/1471-5945-12-3     Document Type: Article

References (18)

1. Elias PM, Hatano Y, Williams ML. Basis for the barrier abnormality in atopic dermatitis: outside-inside-outside pathogenic mechanisms. J Allergy Clin Immunol 2008, 121:1337-1343. 10.1016/j.jaci.2008.01.022, 2706021, 18329087.
2. Palmer CN, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, Goudie DR, Sandilands A, Campbell LE, Smith FJ, O'Regan GM, Watson RM, Cecil JE, Bale SJ, Compton JG, DiGiovanna JJ, Fleckman P, Lewis-Jones S, Arseculeratne G, Sergeant A, Munro CS, El Houate B, McElreavey K, Halkjaer LB, Bisgaard H, Mukhopadhyay S, McLean WH. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet 2006, 38:441-446. 10.1038/ng1767, 16550169.
3. van den Oord RA, Sheikh A. Filaggrin gene defects and risk of developing allergic sensitisation and allergic disorders: systematic review and meta-analysis. BMJ 2009, 339:b2433. 10.1136/bmj.b2433, 2714678, 19589816.
4. Lowe AJ, Carlin JB, Bennett CM, Hosking CS, Abramson MJ, Hill DJ, Dharmage SC. Do boys do the atopic march while girls dawdle?. J Allergy Clin Immunol 2008, 121:1190-1195. 10.1016/j.jaci.2008.01.034, 18313134.
5. Nikolovski J, Stamatas GN, Kollias N, Wiegand BC. Barrier function and water-holding and transport properties of infant stratum corneum are different from adult and continue to develop through the first year of life. J Invest Dermatol 2008, 128:1728-1736. 10.1038/sj.jid.5701239, 18200056.
6. Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003, 112:S118-S127. 10.1016/j.jaci.2003.09.033, 14657842.
7. Demehri S, Morimoto M, Holtzman MJ, Kopan R. Skin-Derived TSLP Triggers Progression from Epidermal-Barrier Defects to Asthma. PLoS Biol 2009, 7:e1000067. 10.1371/journal.pbio.1000067, 2700555, 19557146.
8. Mao-Qiang M, Feingold KR, Thornfeldt CR, Elias PM. Optimization of physiological lipid mixtures for barrier repair. J Invest Dermatol 1996, 106:1096-1101. 10.1111/1523-1747.ep12340135, 8618046.
9. Sugarman JL, Parish LC. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009, 8:1106-1111.
10. Williams HC, Burney PG, Pembroke AC, Hay RJ. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. III. Independent hospital validation. Br J Dermatol 1994, 131:406-416. 10.1111/j.1365-2133.1994.tb08532.x, 7918017.
11. Simpson EL, Berry TM, Brown PA, Hanifin JM. A pilot study of emollient therapy for the primary prevention of atopic dermatitis. J Am Acad Dermatol 2010, 63:587-593. 10.1016/j.jaad.2009.11.011, 3156679, 20692725.
12. Elias PM. Barrier-repair therapy for atopic dermatitis: corrective lipid biochemical therapy. Expert Rev Dermatol 2008, 3:441-452.
13. Miller DW, Koch SB, Yentzer BA, Clark AR, O'Neill JR, Fountain J, Weber TM, Fleischer AB. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011, 10:531-537.
14. Jungersted JM, Scheer H, Mempel M, Baurecht H, Cifuentes L, Hogh JK, Hellgren LI, Jemec GB, Agner T, Weidinger S. Stratum corneum lipids, skin barrier function and filaggrin mutations in patients with atopic eczema. Allergy 2010, 65:911-918. 10.1111/j.1398-9995.2010.02326.x, 20132155.
15. Mao-Qiang M, Brown BE, Wu-Pong S, Feingold KR, Elias PM. Exogenous nonphysiologic vs physiologic lipids. Divergent mechanisms for correction of permeability barrier dysfunction. Arch Dermatol 1995, 131:809-816. 10.1001/archderm.1995.01690190063012, 7611797.
16. Hachem JP, Crumrine D, Fluhr J, Brown BE, Feingold KR, Elias PM. pH directly regulates epidermal permeability barrier homeostasis, and stratum corneum integrity/cohesion. J Invest Dermatol 2003, 121:345-353. 10.1046/j.1523-1747.2003.12365.x, 12880427.
17. Uchida Y, Holleran WM, Elias PM. On the effects of topical synthetic pseudoceramides: comparison of possible keratinocyte toxicities provoked by the pseudoceramides, PC104 and BIO391, and natural ceramides. J Dermatol Sci 2008, 51:37-43. 10.1016/j.jdermsci.2008.02.007, 2410086, 18396015.
18. Halkjaer LB, Loland L, Buchvald FF, Agner T, Skov L, Strand M, Bisgaard H. Development of atopic dermatitis during the first 3 years of life: the Copenhagen prospective study on asthma in childhood cohort study in high-risk children. Arch Dermatol 2006, 142:561-566. 10.1001/archderm.142.5.561, 16702493.